Ambu's goals for the new 2021/2022 financial year are considerably more conservative than what the market had hoped for.
Prior to the medtech company's report, analysts had estimated a financial guidance with an organic growth of around 20 percent, but Ambu reports today that 2021/2022 will deliver organic growth between 15 and 19 percent, according to their guidelines.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.